Biocon Q1 FY27 Earnings Call — Analysis (NSE: BIOCON)
Biocon Q1 FY27 biosimilars up 16%, generics turns profitable, Syngene decline drives mixed start; management targets H2 acceleration and Syngene recovery.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Biosimilars revenue ₹2,855 Cr ( +16% YoY ) . New guidance — FY27 syngene fy27 financial performa… single-digit revenue degrowth; EBITDA margins back to mid-20s . New story: Biosimilar H2 acceleration fueled by new launch… .
Results
Group operating revenue grew 10% YoY; biosimilars up 16% (₹2,855 Cr), generics up 21% (₹760 Cr, EBITDA margin +250bps QoQ), services down 16% (₹736 Cr); EBITDA ₹902 Cr (21% margin); net profit before exceptionals ₹145 Cr (+245% YoY); interest cost down 23% YoY.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Group EBITDA | ₹902 Cr | +na | none · Q1FY27 |
| Group EBITDA margin | 21% | +na | none · Q1FY27 |
| Biosimilars revenue | ₹2,855 Cr | +16% | yoy · Q1FY27 |
| Biosimilars EBITDA | ₹728 Cr | +10% | yoy · Q1FY27 |
| Biosimilars EBITDA margin | 25% | +na | point_in_time · Q1FY27 |
| Generics revenue | ₹760 Cr | +21% | yoy · Q1FY27 |
| Generics EBITDA | ₹56 Cr | +na | none · Q1FY27 |
| Generics EBITDA margin | 7% | +250bps | qoq · Q1FY27 · improvement over Q4FY26 |
| Services revenue | ₹736 Cr | -16% | yoy · Q1FY27 |
| Services operating EBITDA margin | 12% | +na | point_in_time · Q1FY27 |
| Reported net profit before exceptionals | ₹145 Cr | +245% | yoy · Q1FY27 |
| Interest cost | ₹213 Cr | -23% YoY, -8% QoQ | yoy · Q1FY27 |
Guidance
Syngene guided for single-digit revenue degrowth and EBITDA margins back to mid-20s in FY27; biosimilars expected to see meaningful H2 acceleration largely from new launches.
What management committed to
- Biosimilars momentum to build progressively through FY27 with meaningful acceleration in the second half. — FY27
- Supplies from the second drug product line at the [Malaysia insulin facility] should pick up further from Q2 FY27. — Q2FY27
- Syngene full-year FY27 single-digit revenue degrowth (in rupee terms) and EBITDA margins back to mid-20s. — single-digit revenue degrowth; EBITDA margins back to mid-20s, FY27
- [Aflibercept (Yesafili) launch] is going to be a big contributor to growth this fiscal [FY27]. — FY27
- [Biocon] will launch at least one new product in the US or Europe every year through the end of the decade. — one new product launch either in the US or in Europe every year, FY30
- Syngene will return to profitable and sustainable growth from FY28. — FY28
Key themes
Biosimilar H2 build-up, generics turnaround, Syngene transition year
How the narrative shifted
- Biosimilar H2 acceleration fueled by new launches: Management expects a sharp ramp in biosimilars revenue in H2 FY27 driven by recent launches (Aflibercept, Denosumab, Aspart) and contracting cycles, positioning biosimilars as the primary growth engine.
- Generics profitability turnaround in progress: Generics margins have started to improve through product mix, cost synergies and disciplined R&D, with further scale-up expected as new launches (liraglutide) ramp.
- Syngene transition year with H2 recovery: Syngene faces a demand gap from a key biologics client but expects a back-half improvement to deliver only single-digit degrowth; the focus is on restoring commercial momentum and margins.
- Integration synergies driving cost optimization: The merger of Biocon and Biologics is unlocking operating and R&D synergies, enabling hard look at opex and "cutting the fat, not muscle" to sustainably improve profitability across businesses.
- Favorable US policy environment for biosimilars: Management highlights legislative and regulatory initiatives aimed at removing biosimilar adoption barriers and bipartisan support for affordability, reinforcing the long-term opportunity.
Operational commentary
- Received EMA approval for the second drug product line at the Malaysia insulin facility; supplies commenced and expected to ramp from Q2 FY27 to support global insulin demand.
- Launched biosimilar aflibercept (Yesafili) in the US in August 2026, the first biosimilar in ophthalmology; management expects significant revenue contribution in FY27.
- Launched denosumab biosimilars (Bosaya/Aukelso) across multiple European markets and Yesafili in Malaysia; expanded commercial footprint through partnerships in France, Portugal, Slovenia, Spain.
- Generics GLP-1 portfolio driven by liraglutide, with contributions in US and other markets; generics segment achieved over 250 bps sequential margin improvement.
- Syngene entered strategic collaboration with BRIC-THSTI to strengthen translational research and clinical development capabilities; continued advancing SynAI AI-enabled drug discovery platform.
- Integration synergies from merging Biocon and Biologics businesses continue to drive cost optimization across R&D, operations and enabling functions.
Analyst Q&A
Q. Generics base business growth ex-liraglutide and margin movement
Liraglutide contribution in Q1 was single-digit; difficult to give precise movement between base and new launches. Opex reduction across all three companies is a key driver.
Q. Whether biosimilar EBITDA margins will improve vs FY26 levels
Management directed to mid-20s range, noted Q3 FY26 had elevated margins due to product allocation; normalized FY26 margin at ~24-25%, and they are driving expansion.
Q. Impact of US tariffs on biosimilars/generics
Detailed explanation that current US law exempts generics and biosimilars; tariff tweet would require legislative change and likely face bipartisan opposition on affordability grounds.
Research and educational content only. Not investment advice.